TITLE

Potential for False-Positive Staining With a Rabbit Monoclonal Antibody to Progesterone Receptor (SP2): Findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH Highlight the Need for Correct Validation of Antibodies on Introduction to the Laboratory

AUTHOR(S)
Merdol Ibrahim; Andrew Dodson; Sarah Barnett; David Fish; Bharat Jasani; Keith Miller
PUB. DATE
March 2008
SOURCE
American Journal of Clinical Pathology;Mar2008, Vol. 129 Issue 3, p398
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This study focused on recent assessment results from the United Kingdom National External Quality Assessment Scheme for Immunocytochemistry and Fluorescence In-Situ Hybridisation breast hormone receptor module in which participants were asked to demonstrate progesterone receptors (PRs). The slides consisted of 3 infiltrating ductal breast carcinomas, previously classified as a high PR expresser, a moderate to low PR expresser, and a negative tumor.During this assessment, 2 commercial rabbit monoclonal antibodies, SP2 (Lab Vision/NeoMarkers, Fremont, CA), and 1E2 (Ventana, Tucson, AZ) were used by 15% of the participants. The SP2 rabbit monoclonal antibody showed false-positive and nonspecific staining on the previously established PR-tumor. This article highlights the necessity for all clinical laboratories to validate immunohistochemical methods and protocols when using newly marketed antibodies such as SP2; use composite tissue blocks with known levels of tumor expression such as a high, mid, and negative expression; and participate in internal and external quality assessment schemes, which can highlight potential technical issues in laboratory methods.
ACCESSION #
46877942

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics